Every breath sustains life, though few recognize how routine decisions shape respiratory wellness. Innovative interventions, ...

The fungal lung infection has historically been most common around the Central Valley — but that's now changed as cases have ...

In a significant research advancement that may help inform treatment strategies for millions of patients worldwide, a ...

Jonathan Thompson, MD, MS, emphasized that broader molecular testing in early-stage non–small cell lung cancer (NSCLC) is essential to guide perioperative treatment decisions, while selective ...

Merck MRK announced that the FDA has granted the Breakthrough Therapy designation (BTD) to its B7-H3-directed DXd antibody-drug conjugate (ADC), ifinatamab deruxtecan (I-DXd), for treating adult ...

An executive cites the company's 140-year track record as it faces federal action on drug pricing and industry tariffs.

The FDA granted breakthrough therapy designation to Ifinatamab deruxtecan for some with extensive-stage small cell lung ...

The A5 nanobody is around 10 times smaller than conventional antibodies, helping it to penetrate deep into tissues. Crucially, it can bind selectively to cancer cells, leading to a reduction of more ...

BC, AOCNP, explained that adverse effects are common among the available antibody-drug conjugates in breast cancer.

In 2021, ATYR completed a phase 1b/2a trial in pulmonary sarcoidosis, and have since started a phase 3 trial. Currently the ...

For the first time in 30 years, the American Academy of Pediatrics is substantially diverging from U.S. government vaccine ...

The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to ifinatamab deruxtecan for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) ...